Pfizer may be receiving full FDA approval soon, but it probably shouldn’t.

Covid-19 Delta is proving to be more contagious than earlier variants, and hospitals worry they may not be able to keep pace with new cases, but there is no evidence that it is more lethal. Its current fatality rate of 1.7% (down from Alpha’s 3%) is still higher than that of the common flu, yet lower than H1N1’s 4% at the height of the Swine Flu pandemic.

People with comorbidities that put them at higher risk for severe and fatal illness, and men who are concerned about their fertility should undoubtedly consider vaccinations, but not all vaccines are created equal. mRNA’s side-effects are rare, but not insignificant, and the long-term effects (including issues with female fertility and premature menopause) are still unknown. Each of us should consult with a physician about prevention and treatment options to decide what is best for ourselves and our children, but that decision may soon be taken out of our own hands.

Under normal circumstances, the FDA requires 12-15 years of research and development before granting a drug their full approval, but the New York Times is reporting that the FDA may be granting Pfizer full approval for its Covid-19 mRNA vaccine as soon as Monday (23 August 2021). Reuters suggests that this would help state and local authorities overcome hesitancy to impose vaccine mandates. Likely… since the main argument against such measures has been that it is a crime against humanity to force experimental medicine on the general public. If mandates are imposed, they could include children as young as six-months-old.

Moderna has also applied for full FDA approval, but their process may have hit a snag. Their vaccine has shown to present “a higher risk of a heart condition in younger adults than previously believed”, and their EUA for adolescents has been put on hold. One person “familiar with the review” told the Washington Post that they have not yet concluded whether Pfizer’s vaccine holds an equal risk, but former studies conducted by the US military showed a direct correlation between both mRNA vaccines and myocarditis.

The CDC also confirmed that mRNA vaccines lose effectiveness over time and would require continuous booster shots.

Current CDC guidelines recommend mRNA booster every eight months, but some US State Health Departments consider those who have not received an mRNA dose within the previous three months to be “no longer fully vaccinated“, which would suggest that after three months, an mRNA vaccinated person is not protected any more than an unvaccinated person is.

This definition also suggests that the public is being misinformed about our Covid statistics, since many who are reported as “not fully vaccinated” may have indeed been double-jabbed.

What’s more: Nanoparticles used in mRNA technology have long been known to harmfully accumulate in human organs, and Moderna’s own SEC filing admits that LNP’s have lead to “significant adverse events” in previous mRNA trials.

“Certain aspects of our investigational medicines may induce immune reactions from either the mRNA or the lipid as well as adverse reactions within liver pathways or degradation of the mRNA or the LNP, any of which could lead to significant adverse events in one or more of our clinical trials. Many of these types of side effects have been seen for previously developed LNPs.” (Page 80)

Despite its questionable efficacy, the myriad of rare but significant side-effects, and the possibility of long term harmful effects, the CDC still insists that mRNA is better for us than the disease. But with the existence of safer, more effective vaccines (the J&J) and therapeutics (like Regeneron), and the virus itself mutating into less lethal variants for the sake of its own survival and co-existence with humankind… I’m not sure that the benefits of mRNA still outweigh its risks.


 

One response to “Pfizer may be receiving full FDA approval soon, but it probably shouldn’t.

Leave a Reply

Your email address will not be published. Required fields are marked *